


Supplemental Figure. Flow diagram of the participant selection for analysis of the association between ART adherence and biomarkers of inflammation and coagulopathy at the time of enrollment in SMART.



SMART: Strategies for Management of Antiretroviral Therapy. ART: Antiretroviral therapy. HIV VL: HIV viral load. IL-6: interleukin-6. hsCRP: high-sensitivity C-reactive protein. *A total of 589 participants with an HIV VL <400 copies/mL were excluded from the analysis.

1 **Supplementary Table. Sensitivity analysis restricting the sample size to PLWH who were virologically suppressed to <50 copies/mL while on ART upon**
2 **enrollment in SMART.**

Biomarker	100% adherence		Suboptimal adherence		Unadjusted analysis			Adjusted analysis ^a		
	N	Mean (SD)	N	Mean (SD)	Fold higher level compared to 100% adherence ^b	95% CI	P-value	Fold higher level compared to 100% adherence ^b	95% CI	P-value
IL-6 (pg/mL)	1,807	2.54 (7.62)	289	2.93 (4.72)	1.19	1.08-1.30	0.0005	1.11	1.01-1.21	0.02
D-dimer (µg/mL)	1,814	0.28 (0.40)	291	0.41 (1.22)	1.21	1.08-1.36	0.0008	1.13	1.01-1.27	0.03
hsCRP (µg/mL)	1,828	3.52 (6.02)	293	4.56 (8.27)	1.14	0.98-1.32	0.10	1.08	0.93-1.26	0.29

3

4 ^aModels were adjusted for covariates including age, race, gender, body mass index, time on ART, HIV exposure group, baseline viral load, baseline and nadir CD4⁺ T-cells,
5 hepatitis B or C co-infection, smoking and regimen type. ^b100% adherence defined as no report of any missed doses for any drug in the preceding 7-day period. PLWH:
6 people living with HIV; ART: antiretroviral therapy; IL-6: interleukin 6. hsCRP: high-sensitivity C-reactive protein. SD: standard deviation. 95% CI: 95% confidence
7 interval.